Company Profile
Calliditas Therapeutics AB Stock Price, News & Catalysts
- Ticker:
- CALT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Sweden
Why the stock is moving
Current closing-price context is not available for CALT.
Company overview
Business overview
Calliditas Therapeutics was a rare-disease and kidney-disease company focused on IgA nephropathy and related conditions before becoming a historical ticker. Its business reflected the value of specialty renal therapeutics in orphan disease.
Geographic Base and Sector Classification
Calliditas was headquartered in Sweden and listed on NASDAQ. It sat in rare-disease biotechnology.
Business Model Characteristics
The company depended on clinical success, label expansion, and commercial execution in a focused nephrology market. Investors watched regulatory progress and launch performance.
Position Within the Biotechnology Landscape
Calliditas belongs to the historical rare-disease kidney bucket. It was a premium specialty biotech story before its strategic transition and legacy status.
Future catalysts
- Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it like a live growth name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Calliditas Therapeutics AB do?
Calliditas Therapeutics was a rare-disease and kidney-disease company focused on IgA nephropathy and related conditions before becoming a historical ticker. Its business reflected the value of specialty renal therapeutics in orphan disease.
On which exchange is CALT stock listed?
Calliditas Therapeutics AB (CALT) is associated with NASDAQ, Sweden, Biopharma.
What is Calliditas?
Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update.
Which conditions is Calliditas Therapeutics AB targeting with Calliditas?
Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update.
How does Calliditas Therapeutics AB describe recent progress with Calliditas?
Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update.
What is Therapeutics?
Calliditas Therapeutics was a rare-disease and kidney-disease company focused on IgA nephropathy and related conditions before becoming a historical ticker.
What should investors watch for with Therapeutics?
Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it like a live growth name.
What future catalysts are investors watching for Calliditas Therapeutics AB?
Calliditas is now largely a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. The market no longer treats it like a live growth name.